An integrated gene-to-outcome multimodal database for metabolic dysfunction-associated steatotic liver disease
© 2023. The Author(s)..
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the commonest cause of chronic liver disease worldwide and represents an unmet precision medicine challenge. We established a retrospective national cohort of 940 histologically defined patients (55.4% men, 44.6% women; median body mass index 31.3; 32% with type 2 diabetes) covering the complete MASLD severity spectrum, and created a secure, searchable, open resource (SteatoSITE). In 668 cases and 39 controls, we generated hepatic bulk RNA sequencing data and performed differential gene expression and pathway analysis, including exploration of gender-specific differences. A web-based gene browser was also developed. We integrated histopathological assessments, transcriptomic data and 5.67 million days of time-stamped longitudinal electronic health record data to define disease-stage-specific gene expression signatures, pathogenic hepatic cell subpopulations and master regulator networks associated with adverse outcomes in MASLD. We constructed a 15-gene transcriptional risk score to predict future hepatic decompensation events (area under the receiver operating characteristic curve 0.86, 0.81 and 0.83 for 1-, 3- and 5-year risk, respectively). Additionally, thyroid hormone receptor beta regulon activity was identified as a critical suppressor of disease progression. SteatoSITE supports rational biomarker and drug development and facilitates precision medicine approaches for patients with MASLD.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:29 |
|---|---|
| Enthalten in: |
Nature medicine - 29(2023), 11 vom: 19. Nov., Seite 2939-2953 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kendall, Timothy J [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 27.11.2023 Date Revised 20.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41591-023-02602-2 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM363958436 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM363958436 | ||
| 003 | DE-627 | ||
| 005 | 20240320233610.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41591-023-02602-2 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1337.xml |
| 035 | |a (DE-627)NLM363958436 | ||
| 035 | |a (NLM)37903863 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kendall, Timothy J |e verfasserin |4 aut | |
| 245 | 1 | 3 | |a An integrated gene-to-outcome multimodal database for metabolic dysfunction-associated steatotic liver disease |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.11.2023 | ||
| 500 | |a Date Revised 20.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s). | ||
| 520 | |a Metabolic dysfunction-associated steatotic liver disease (MASLD) is the commonest cause of chronic liver disease worldwide and represents an unmet precision medicine challenge. We established a retrospective national cohort of 940 histologically defined patients (55.4% men, 44.6% women; median body mass index 31.3; 32% with type 2 diabetes) covering the complete MASLD severity spectrum, and created a secure, searchable, open resource (SteatoSITE). In 668 cases and 39 controls, we generated hepatic bulk RNA sequencing data and performed differential gene expression and pathway analysis, including exploration of gender-specific differences. A web-based gene browser was also developed. We integrated histopathological assessments, transcriptomic data and 5.67 million days of time-stamped longitudinal electronic health record data to define disease-stage-specific gene expression signatures, pathogenic hepatic cell subpopulations and master regulator networks associated with adverse outcomes in MASLD. We constructed a 15-gene transcriptional risk score to predict future hepatic decompensation events (area under the receiver operating characteristic curve 0.86, 0.81 and 0.83 for 1-, 3- and 5-year risk, respectively). Additionally, thyroid hormone receptor beta regulon activity was identified as a critical suppressor of disease progression. SteatoSITE supports rational biomarker and drug development and facilitates precision medicine approaches for patients with MASLD | ||
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Jimenez-Ramos, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Turner, Frances |e verfasserin |4 aut | |
| 700 | 1 | |a Ramachandran, Prakash |e verfasserin |4 aut | |
| 700 | 1 | |a Minnier, Jessica |e verfasserin |4 aut | |
| 700 | 1 | |a McColgan, Michael D |e verfasserin |4 aut | |
| 700 | 1 | |a Alam, Masood |e verfasserin |4 aut | |
| 700 | 1 | |a Ellis, Harriet |e verfasserin |4 aut | |
| 700 | 1 | |a Dunbar, Donald R |e verfasserin |4 aut | |
| 700 | 1 | |a Kohnen, Gabriele |e verfasserin |4 aut | |
| 700 | 1 | |a Konanahalli, Prakash |e verfasserin |4 aut | |
| 700 | 1 | |a Oien, Karin A |e verfasserin |4 aut | |
| 700 | 1 | |a Bandiera, Lucia |e verfasserin |4 aut | |
| 700 | 1 | |a Menolascina, Filippo |e verfasserin |4 aut | |
| 700 | 1 | |a Juncker-Jensen, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Alexander, Douglas |e verfasserin |4 aut | |
| 700 | 1 | |a Mayor, Charlie |e verfasserin |4 aut | |
| 700 | 1 | |a Guha, Indra Neil |e verfasserin |4 aut | |
| 700 | 1 | |a Fallowfield, Jonathan A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nature medicine |d 1995 |g 29(2023), 11 vom: 19. Nov., Seite 2939-2953 |w (DE-627)NLM074659804 |x 1546-170X |7 nnns |
| 773 | 1 | 8 | |g volume:29 |g year:2023 |g number:11 |g day:19 |g month:11 |g pages:2939-2953 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41591-023-02602-2 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 29 |j 2023 |e 11 |b 19 |c 11 |h 2939-2953 | ||